These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

558 related items for PubMed ID: 25975443

  • 1. Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation.
    Nazeef M, Kahl BS.
    Curr Treat Options Oncol; 2015 Jun; 16(6):29. PubMed ID: 25975443
    [Abstract] [Full Text] [Related]

  • 2. Current treatment approaches for mantle-cell lymphoma.
    Witzig TE.
    J Clin Oncol; 2005 Sep 10; 23(26):6409-14. PubMed ID: 16155027
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma.
    Till BG.
    Curr Treat Options Oncol; 2018 Jul 21; 19(9):45. PubMed ID: 30032463
    [Abstract] [Full Text] [Related]

  • 5. Mantle cell lymphoma: therapeutic options in transplant-ineligible patients.
    Robak T, Smolewski P, Robak P, Dreyling M.
    Leuk Lymphoma; 2019 Nov 21; 60(11):2622-2634. PubMed ID: 31018735
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
    Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W, Study group indolent Lymphomas (StiL).
    Lancet; 2013 Apr 06; 381(9873):1203-10. PubMed ID: 23433739
    [Abstract] [Full Text] [Related]

  • 10. R-CHOP or R-HyperCVAD with or without autologous stem cell transplantation for older patients with mantle cell lymphoma.
    Frosch Z, Luskin MR, Landsburg DJ, Schuster SJ, Svoboda J, Loren AW, Porter DL, Stadtmauer EA, Nasta SD.
    Clin Lymphoma Myeloma Leuk; 2015 Feb 06; 15(2):92-7. PubMed ID: 25174772
    [Abstract] [Full Text] [Related]

  • 11. Treatment of older patients with mantle-cell lymphoma.
    Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, Stilgenbauer S, Thieblemont C, Vehling-Kaiser U, Doorduijn JK, Coiffier B, Forstpointner R, Tilly H, Kanz L, Feugier P, Szymczyk M, Hallek M, Kremers S, Lepeu G, Sanhes L, Zijlstra JM, Bouabdallah R, Lugtenburg PJ, Macro M, Pfreundschuh M, Procházka V, Di Raimondo F, Ribrag V, Uppenkamp M, André M, Klapper W, Hiddemann W, Unterhalt M, Dreyling MH.
    N Engl J Med; 2012 Aug 09; 367(6):520-31. PubMed ID: 22873532
    [Abstract] [Full Text] [Related]

  • 12. What is the optimal initial management of the older MCL patient?
    Kluin-Nelemans JC, Doorduijn JK.
    Best Pract Res Clin Haematol; 2018 Mar 09; 31(1):99-104. PubMed ID: 29452672
    [Abstract] [Full Text] [Related]

  • 13. [Treatment for mantle cell lymphoma].
    Izutsu K.
    Rinsho Ketsueki; 2017 Mar 09; 58(10):2026-2032. PubMed ID: 28978845
    [Abstract] [Full Text] [Related]

  • 14. Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial.
    Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Geisler CH, Trneny M, Stilgenbauer S, Kaiser F, Doorduijn JK, Salles G, Szymczyk M, Tilly H, Kanz L, Schmidt C, Feugier P, Thieblemont C, Zijlstra JM, Ribrag V, Klapper W, Pott C, Unterhalt M, Dreyling MH.
    J Clin Oncol; 2020 Jan 20; 38(3):248-256. PubMed ID: 31804876
    [Abstract] [Full Text] [Related]

  • 15. Superiority of ibrutinib plus bendamustine and rituximab in newly diagnosed patients with mantle-cell lymphoma ineligible for intensive therapy: A network meta-analysis.
    Sheng Z, Wang L.
    Eur J Haematol; 2023 Jun 20; 110(6):602-607. PubMed ID: 36919283
    [Abstract] [Full Text] [Related]

  • 16. Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.
    Till BG, Li H, Bernstein SH, Fisher RI, Burack WR, Rimsza LM, Floyd JD, DaSilva MA, Moore DF, Pozdnyakova O, Smith SM, LeBlanc M, Friedberg JW.
    Br J Haematol; 2016 Jan 20; 172(2):208-18. PubMed ID: 26492567
    [Abstract] [Full Text] [Related]

  • 17. Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma.
    Villa D, Sehn LH, Savage KJ, Toze CL, Song K, den Brok WD, Freeman CL, Scott DW, Gerrie AS.
    Blood Adv; 2020 Aug 11; 4(15):3486-3494. PubMed ID: 32735654
    [Abstract] [Full Text] [Related]

  • 18. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
    Nickenig C, Dreyling M, Hoster E, Pfreundschuh M, Trumper L, Reiser M, Wandt H, Lengfelder E, Unterhalt M, Hiddemann W, German Low-Grade Lymphoma Study Group.
    Cancer; 2006 Sep 01; 107(5):1014-22. PubMed ID: 16878325
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.